This Is MS Multiple Sclerosis Community: Knowledge & Support
Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
Xenetic Biosciences has completed the Phase I, safety trial for its multiple sclerosis (MS) treatment MyeloXen and is now treating patients to establish dosing levels.
The Phase I trial passed without any adverse event on six healthy volunteers and its Russian partner, Pharmsynthez, has now started Phase II where 12 patients will receive escalating dosing levels to establish the safe dose level for MyeloXen...... Read More - http://www.ms-uk.org/index.cfm/MSnews
Have to agree with you on this one, Cure. More drugs to try and control the immune system of a MS patient when we don't even know the etiology of MS in the first place. But hey, the money to be made off MS with anything new that shows promise (marketing/sales strategy) can be quite rewarding.